Cite
Wilkinson S, Ye H, Karzai F, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. 2021;80(6):746-757doi: 10.1016/j.eururo.2021.03.009.
Wilkinson, S., Ye, H., Karzai, F., Harmon, S. A., Terrigino, N. T., VanderWeele, D. J., Bright, J. R., Atway, R., Trostel, S. Y., Carrabba, N. V., Whitlock, N. C., Walker, S. M., Lis, R. T., Abdul Sater, H., Capaldo, B. J., Madan, R. A., Gulley, J. L., Chun, G., Merino, M. J., Pinto, P. A., Salles, D. C., Kaur, H. B., Lotan, T. L., Venzon, D. J., Choyke, P. L., Turkbey, B., Dahut, W. L., & Sowalsky, A. G. (2021). Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European urology, 80(6), 746-757. https://doi.org/10.1016/j.eururo.2021.03.009
Wilkinson, Scott, et al. "Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy." European urology vol. 80,6 (2021): 746-757. doi: https://doi.org/10.1016/j.eururo.2021.03.009
Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, Madan RA, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL, Sowalsky AG. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. 2021 Dec;80(6):746-757. doi: 10.1016/j.eururo.2021.03.009. Epub 2021 Mar 27. PMID: 33785256; PMCID: PMC8473585.
Copy
Download .nbib